{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T18:17:23Z","timestamp":1770833843065,"version":"3.50.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,10,12]],"date-time":"2021-10-12T00:00:00Z","timestamp":1633996800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,12]],"date-time":"2021-10-12T00:00:00Z","timestamp":1633996800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Youth Foundation of Zhejiang Academy of Medical Sciences","award":["CF2008Q04"],"award-info":[{"award-number":["CF2008Q04"]}]},{"name":"Youth Foundation of Zhejiang Academy of Medical Sciences","award":["1907Q"],"award-info":[{"award-number":["1907Q"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81773626"],"award-info":[{"award-number":["81773626"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Bioinformatics"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Detecting prostate cancer at a non-aggressive stage is the main goal of prostate cancer screening. DNA methylation has been widely used as biomarkers for cancer diagnosis and prognosis, however, with low clinical translation rate. By taking advantage of multi-cancer data from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO), we aimed to identify prostate cancer specific biomarkers which can separate between non-aggressive and aggressive prostate cancer based on DNA methylation patterns.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We performed a comparison analysis of DNA methylation status between normal prostate tissues and prostate adenocarcinoma (PRAD) samples at different Gleason stages. The candidate biomarkers were selected by excluding the biomarkers existing in multiple cancers (pan-cancer) and requiring significant difference between PRAD and other urinary samples. By least absolute shrinkage and selection operator (LASSO) selection, 8 biomarkers (cg04633600, cg05219445, cg05796128, cg10834205, cg16736826, cg23523811, cg23881697, cg24755931) were identified and in-silico validated by model constructions. First, all 8 biomarkers could separate PRAD at different stages (Gleason 6 vs. Gleason 3\u2009+\u20094: AUC\u2009=\u20090.63; Gleason 6 vs. Gleason 4\u2009+\u20093 and 8\u201310: AUC\u2009=\u20090.87). Second, 5 biomarkers (cg04633600, cg05796128, cg23523811, cg23881697, cg24755931) effectively detected PRAD from normal prostate tissues (AUC ranged from 0.88 to 0.92). Last, 6 biomarkers\u00a0(cg04633600, cg05219445, cg05796128, cg23523811, cg23881697, cg24755931) completely distinguished PRAD with other urinary samples (AUC\u2009=\u20091).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our study identified and in-silico validated a panel of prostate cancer specific DNA methylation biomarkers with diagnosis value.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12859-021-04416-w","type":"journal-article","created":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T01:03:50Z","timestamp":1634087030000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Identification of prostate cancer specific methylation biomarkers from a multi-cancer analysis"],"prefix":"10.1186","volume":"22","author":[{"given":"Yiyi","family":"Pu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haining","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoju","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,10,12]]},"reference":[{"issue":"6","key":"4416_CR1","first-page":"394","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer J Clin. 2018;68(6):394\u2013424.","journal-title":"CA: A Cancer J Clin"},{"issue":"6","key":"4416_CR2","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1016\/j.mcna.2020.08.007","volume":"104","author":"SV Carlsson","year":"2020","unstructured":"Carlsson SV, Vickers AJ. Screening for prostate cancer. Med Clin North Am. 2020;104(6):1051\u201362.","journal-title":"Med Clin North Am"},{"issue":"17","key":"4416_CR3","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1056\/NEJM199104253241702","volume":"324","author":"WJ Catalona","year":"1991","unstructured":"Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJ, Petros JA, Andriole GL. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med. 1991;324(17):1156\u201361.","journal-title":"N Engl J Med"},{"issue":"3 Part 2","key":"4416_CR4","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/S0022-5347(17)37401-3","volume":"147","author":"MK Brawer","year":"1992","unstructured":"Brawer MK, Chetner MP, Beatie J, Buchner DM, Vessella RL, Lange PH. Screening for prostatic carcinoma with prostate specific antigen. J Urol. 1992;147(3 Part 2):841\u20135.","journal-title":"J Urol"},{"issue":"6","key":"4416_CR5","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1016\/j.eururo.2013.12.062","volume":"65","author":"S Loeb","year":"2014","unstructured":"Loeb S, Bjurlin MA, Nicholson J, Tammela TL, Penson DF, Carter HB, Carroll P, Etzioni R. Overdiagnosis and overtreatment of prostate cancer. Eur Urol. 2014;65(6):1046\u201355.","journal-title":"Eur Urol"},{"issue":"18","key":"4416_CR6","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1001\/jama.2018.3710","volume":"319","author":"USPST Force","year":"2018","unstructured":"Force USPST, Grossman DC, Curry SJ, Owens DK, Bibbins-Domingo K, Caughey AB, Davidson KW, Doubeni CA, Ebell M, Epling JW Jr, et al. Screening for prostate cancer: US preventive services task force recommendation statement. JAMA. 2018;319(18):1901\u201313.","journal-title":"JAMA"},{"issue":"4","key":"4416_CR7","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/nrc1045","volume":"3","author":"PW Laird","year":"2003","unstructured":"Laird PW. The power and the promise of DNA methylation markers. Nat Rev Cancer. 2003;3(4):253\u201366.","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"4416_CR8","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1038\/cr.2011.24","volume":"21","author":"HC Tsai","year":"2011","unstructured":"Tsai HC, Baylin SB. Cancer epigenetics: linking basic biology to clinical medicine. Cell Res. 2011;21(3):502\u201317.","journal-title":"Cell Res"},{"issue":"7","key":"4416_CR9","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/s41571-018-0004-4","volume":"15","author":"A Koch","year":"2018","unstructured":"Koch A, Joosten SC, Feng Z, de Ruijter TC, Draht MX, Melotte V, Smits KM, Veeck J, Herman JG, Van Neste L, et al. Analysis of DNA methylation in cancer: location revisited. Nat Rev Clin Oncol. 2018;15(7):459\u201366.","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"4416_CR10","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2(5):401\u20134.","journal-title":"Cancer Discov"},{"key":"4416_CR11","volume-title":"AJCC cancer staging manual","author":"SB Edge","year":"2010","unstructured":"Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC cancer staging manual. 7th ed. New York: Springer; 2010.","edition":"7"},{"key":"4416_CR12","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1186\/1471-2105-11-587","volume":"11","author":"P Du","year":"2010","unstructured":"Du P, Zhang X, Huang CC, Jafari N, Kibbe WA, Hou L, Lin SM. Comparison of beta-value and M-value methods for quantifying methylation levels by microarray analysis. BMC Bioinform. 2010;11:587.","journal-title":"BMC Bioinform"},{"issue":"2","key":"4416_CR13","doi-asserted-by":"publisher","first-page":"203","DOI":"10.4161\/epi.23470","volume":"8","author":"YA Chen","year":"2013","unstructured":"Chen YA, Lemire M, Choufani S, Butcher DT, Grafodatskaya D, Zanke BW, Gallinger S, Hudson TJ, Weksberg R. Discovery of cross-reactive probes and polymorphic CpGs in the Illumina Infinium HumanMethylation450 microarray. Epigenetics. 2013;8(2):203\u20139.","journal-title":"Epigenetics"},{"issue":"1","key":"4416_CR14","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/1471-2164-15-51","volume":"15","author":"H Naeem","year":"2014","unstructured":"Naeem H, Wong NC, Chatterton Z, Hong MK, Pedersen JS, Corcoran NM, Hovens CM, Macintyre G. Reducing the risk of false discovery enabling identification of biologically significant genome-wide methylation status using the HumanMethylation450 array. BMC Genomics. 2014;15(1):51.","journal-title":"BMC Genomics"},{"issue":"7","key":"4416_CR15","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, Smyth GK. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47.","journal-title":"Nucleic Acids Res"},{"issue":"3","key":"4416_CR16","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1038\/modpathol.3800054","volume":"17","author":"PA Humphrey","year":"2004","unstructured":"Humphrey PA. Gleason grading and prognostic factors in carcinoma of the prostate. Mod Pathol. 2004;17(3):292\u2013306.","journal-title":"Mod Pathol"},{"issue":"3","key":"4416_CR17","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.eururo.2015.06.046","volume":"69","author":"JI Epstein","year":"2016","unstructured":"Epstein JI, Zelefsky MJ, Sjoberg DD, Nelson JB, Egevad L, Magi-Galluzzi C, Vickers AJ, Parwani AV, Reuter VE, Fine SW, et al. A contemporary prostate cancer grading system: a validated alternative to the gleason score. Eur Urol. 2016;69(3):428\u201335.","journal-title":"Eur Urol"},{"issue":"3","key":"4416_CR18","first-page":"129","volume":"7","author":"KJ Wojno","year":"2014","unstructured":"Wojno KJ, Costa FJ, Cornell RJ, Small JD, Pasin E, Van Criekinge W, Bigley JW, Van Neste L. Reduced rate of repeated prostate biopsies observed in ConfirmMDx clinical utility field study. Am Health Drug Benef. 2014;7(3):129\u201334.","journal-title":"Am Health Drug Benef"},{"issue":"14","key":"4416_CR19","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1002\/pros.23895","volume":"79","author":"PG Patel","year":"2019","unstructured":"Patel PG, Wessel T, Kawashima A, Okello JBA, Jamaspishvili T, Guerard KP, Lee L, Lee AY, How NE, Dion D, et al. A three-gene DNA methylation biomarker accurately classifies early stage prostate cancer. Prostate. 2019;79(14):1705\u201314.","journal-title":"Prostate"},{"issue":"1","key":"4416_CR20","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1186\/s12967-019-2065-2","volume":"17","author":"N Xu","year":"2019","unstructured":"Xu N, Wu YP, Ke ZB, Liang YC, Cai H, Su WT, Tao X, Chen SH, Zheng QS, Wei Y, et al. Identification of key DNA methylation-driven genes in prostate adenocarcinoma: an integrative analysis of TCGA methylation data. J Transl Med. 2019;17(1):311.","journal-title":"J Transl Med"},{"issue":"1","key":"4416_CR21","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s13148-019-0736-8","volume":"11","author":"R Toth","year":"2019","unstructured":"Toth R, Schiffmann H, Hube-Magg C, Buscheck F, Hoflmayer D, Weidemann S, Lebok P, Fraune C, Minner S, Schlomm T, et al. Random forest-based modelling to detect biomarkers for prostate cancer progression. Clin Epigenetics. 2019;11(1):148.","journal-title":"Clin Epigenetics"},{"issue":"1","key":"4416_CR22","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1186\/s12885-019-5403-0","volume":"19","author":"BP de Almeida","year":"2019","unstructured":"de Almeida BP, Apolonio JD, Binnie A, Castelo-Branco P. Roadmap of DNA methylation in breast cancer identifies novel prognostic biomarkers. BMC Cancer. 2019;19(1):219.","journal-title":"BMC Cancer"},{"issue":"11","key":"4416_CR23","doi-asserted-by":"publisher","first-page":"8797","DOI":"10.1002\/jcb.27129","volume":"119","author":"Y Tu","year":"2018","unstructured":"Tu Y, Fan G, Xi H, Zeng T, Sun H, Cai X, Kong W. Identification of candidate aberrantly methylated and differentially expressed genes in thyroid cancer. J Cell Biochem. 2018;119(11):8797\u2013806.","journal-title":"J Cell Biochem"},{"issue":"1","key":"4416_CR24","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s12935-018-0629-5","volume":"18","author":"G Fan","year":"2018","unstructured":"Fan G, Tu Y, Chen C, Sun H, Wan C, Cai X. DNA methylation biomarkers for hepatocellular carcinoma. Cancer Cell Int. 2018;18(1):140.","journal-title":"Cancer Cell Int"},{"issue":"11","key":"4416_CR25","doi-asserted-by":"publisher","first-page":"3029","DOI":"10.1007\/s10620-017-4740-6","volume":"62","author":"H Li","year":"2017","unstructured":"Li H, Liu JW, Liu S, Yuan Y, Sun LP. Bioinformatics-based identification of methylated-differentially expressed genes and related pathways in gastric cancer. Dig Dis Sci. 2017;62(11):3029\u201339.","journal-title":"Dig Dis Sci"},{"issue":"5","key":"4416_CR26","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1097\/PPO.0000000000000279","volume":"23","author":"KW McMahon","year":"2017","unstructured":"McMahon KW, Karunasena E, Ahuja N. The roles of DNA methylation in the stages of cancer. Cancer J. 2017;23(5):257\u201361.","journal-title":"Cancer J"},{"key":"4416_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/PO.2014.58.5729a.2019.1.test","volume":"2019","author":"E O'Reilly","year":"2019","unstructured":"O\u2019Reilly E, Tuzova AV, Walsh AL, Russell NM, O\u2019Brien O, Kelly S, Dhomhnallain ON, DeBarra L, Dale CM, Brugman R, et al. epiCaPture: a urine DNA methylation test for early detection of aggressive prostate cancer. JCO Precis Oncol. 2019;2019:1\u201318.","journal-title":"JCO Precis Oncol"},{"issue":"1","key":"4416_CR28","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/s13148-018-0575-z","volume":"10","author":"F Zhao","year":"2018","unstructured":"Zhao F, Olkhov-Mitsel E, Kamdar S, Jeyapala R, Garcia J, Hurst R, Hanna MY, Mills R, Tuzova AV, O\u2019Reilly E, et al. A urine-based DNA methylation assay, ProCUrE, to identify clinically significant prostate cancer. Clin Epigenetics. 2018;10(1):147.","journal-title":"Clin Epigenetics"},{"issue":"1","key":"4416_CR29","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s13148-019-0716-z","volume":"11","author":"A Bakavicius","year":"2019","unstructured":"Bakavicius A, Daniunaite K, Zukauskaite K, Barisiene M, Jarmalaite S, Jankevicius F. Urinary DNA methylation biomarkers for prediction of prostate cancer upgrading and upstaging. Clin Epigenetics. 2019;11(1):115.","journal-title":"Clin Epigenetics"},{"issue":"8","key":"4416_CR30","doi-asserted-by":"publisher","first-page":"e32","DOI":"10.1093\/nar\/28.8.e32","volume":"28","author":"CA Eads","year":"2000","unstructured":"Eads CA, Danenberg KD, Kawakami K, Saltz LB, Blake C, Shibata D, Danenberg PV, Laird PW. MethyLight: a high-throughput assay to measure DNA methylation. Nucleic Acids Res. 2000;28(8):e32.","journal-title":"Nucleic Acids Res"},{"key":"4416_CR31","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/978-1-4939-7481-8_22","volume":"1708","author":"F Busato","year":"2018","unstructured":"Busato F, Dejeux E, El Abdalaoui H, Gut IG, Tost J. Quantitative DNA methylation analysis at single-nucleotide resolution by pyrosequencing(R). Methods Mol Biol. 2018;1708:427\u201345.","journal-title":"Methods Mol Biol"},{"issue":"38","key":"4416_CR32","doi-asserted-by":"publisher","first-page":"40611","DOI":"10.18632\/oncotarget.6141","volume":"6","author":"L Yao","year":"2015","unstructured":"Yao L, Ren S, Zhang M, Du F, Zhu Y, Yu H, Zhang C, Li X, Yang C, Liu H, et al. Identification of specific DNA methylation sites on the Y-chromosome as biomarker in prostate cancer. Oncotarget. 2015;6(38):40611\u201321.","journal-title":"Oncotarget"}],"container-title":["BMC Bioinformatics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12859-021-04416-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12859-021-04416-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12859-021-04416-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T01:07:23Z","timestamp":1634087243000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcbioinformatics.biomedcentral.com\/articles\/10.1186\/s12859-021-04416-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,12]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["4416"],"URL":"https:\/\/doi.org\/10.1186\/s12859-021-04416-w","relation":{},"ISSN":["1471-2105"],"issn-type":[{"value":"1471-2105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,12]]},"assertion":[{"value":"24 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"492"}}